EEG microstates and inflammatory biomarkers in older adults with major depression receiving ECT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study will compare resting-state EEG microstate parameters before and after electroconvulsive therapy in older adults diagnosed with major depressive disorder or bipolar disorder with a current depressive episode. In parallel, researchers will analyze blood samples for inflammatory cytokines and related biomarkers to see how these change with treatment and relate to clinical improvement. The study uses an observational design to explore associations between neurophysiological changes, inflammatory markers, and psychometric measures in the context of ECT. A healthy control group aged 55 or older will be included to provide baseline biomarker and EEG comparisons, ensuring participants meet safety criteria and provide informed consent. The aim is to better understand potential mechanisms of ECT and identify biomarkers linked to treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patient Group

* Age ≥55 years.
* Diagnosis of Major Depressive Disorder or Bipolar Disorder, current major depressive episode, according to DSM-5 criteria.
* Clinical indication for electroconvulsive therapy (ECT).
* Ability to provide written informed consent.
* Willingness to participate in the study.

Healthy Control Group:

* Age ≥55 years.
* No current psychiatric disorder.
* No known neurological disorder.
* Good general physical health.
* No current use of medications known to affect EEG activity or inflammatory biomarkers significantly.
* Ability to provide written informed consent.
* Willingness to participate in the study.

Exclusion Criteria:

* Primary neurological disorders (e.g., dementia or traumatic brain injury).
* Schizophrenia or other psychotic disorders.
* Intracranial space-occupying lesions.
* Increased intracranial pressure.
* Myocardial infarction within the previous 3 months.
* Cerebrovascular disease within the previous month.
* Unstable cerebral aneurysm.
* Pheochromocytoma.
* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month.
* Cognitive impairment severe enough to prevent adequate cooperation during EEG recording.
* Current alcohol or substance use disorder.
* Active infectious disease.
* Uncontrolled autoimmune or chronic inflammatory disorders. Participants with stable disease who had received the same maintenance treatment within the previous 3 months were eligible for inclusion.

Where it's running

• İstanbul University- Cerrahpasa, Cerrahpasa Medicine Faculty, Psychiatry Department
  Istanbul, Bakırköy, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Zeynep Dagoglu Sarac, Dr
• Email: zod395@gmail.com
• Phone: +905365942469

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EEG microstates and inflammatory markers in treatment-resistant depression patients undergoing ECT

  This study tests how electroconvulsive therapy affects brain activity patterns seen in EEG and inflammatory biomarkers in adults with treatment-resistant major depression.

  Recruiting Istanbul University - Cerrahpasa · Istanbul, Bakırköy · NCT07748091

• Registry for patients with treatment-resistant depression and OCD receiving interventional therapies

  This study is testing different treatments like ECT, TMS, and ketamine to see how they help people with treatment-resistant depression and OCD feel better.

  Recruiting University of Iowa · Iowa City, Iowa · NCT04480918

• Sensation Seeking and TMS Response in TRD: Does Personality Shape Treatment Outcomes?

  This real-world study tests whether people with treatment-resistant depression who have higher sensation-seeking traits respond differently to TMS treatment.

  Recruiting Technical University of Munich · München, Bavaria · NCT07889739

• Remote monitoring for adults with depression using ThIA Suivi

  This study tests whether adding the ThIA Suivi remote monitoring tool to usual psychiatric care helps adults with depression feel more improved after 3 months compared with standard care alone.

  Recruiting at 3 sites Phase 1 ThIA Santé Mentale · Bron and 2 other locations · NCT07878754

• Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder

  This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.

  Recruiting Bosnalijek D.D · Sarajevo · NCT07858565

• SCC Deep Brain Stimulation for Bipolar Depression in Bipolar I Patients

  A small study tests whether deep brain stimulation of the subcallosal cingulate can help people with bipolar I depression who have not improved with other treatments, while monitoring brain signals to watch for manic switches.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT07745374

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.